Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Drug Industry Meets In Shanghai
Pharmaceutical Ingredients: Exhibitors at CPhI China note the country’s increasing sophistication
by Jean-François Tremblay
August 5, 2011
A record 1,700 exhibitors from China and the rest of the world descended on Shanghai this week for the pharmaceutical ingredients trade show CPhI China. The event provided participants another opportunity to witness the growing savvy of China’s fine chemicals industry.
“Chinese companies are learning what foreign customers are looking for,” said William H. Tamblyn, director of technical commercial development at the catalyst supplier Johnson Matthey. “They are offering increasingly sophisticated products made in facilities that have been inspected and certified.”
China exported $4.4 billion worth of pharmaceutical products in 2010, a 30% rise over 2009, according to official customs data.
The event was a forum for Chinese drug ingredient makers to seek out foreign clients. “There are more and more Chinese exhibitors at this trade show, and yet the number of producers in China is actually coming down,” noted Oliver Ju, CEO of China’s Porton Fine Chemicals. Many producers of active pharmaceutical ingredients (APIs) in the coastal province of Zhejiang are struggling with intense cost pressure as they try to meet increasingly strict environmental regulations, Ju explained.
Some Western firms, such as Johnson Matthey, see business potential in the rise of China’s drug industry. “There’s a lot of talk about China’s rising manufacturing costs,” Tamblyn said. “But you can also look at that as rising affluence and therefore a growing Chinese demand for high-quality pharmaceuticals.”
Chemwerth, a U.S. firm that markets APIs made in China, also sees opportunity. “China wants a strong drug industry, and it’s investing in that,” said CEO Peter J. Werth. “Yet Chinese suppliers have still not had much success selling APIs in the U.S. market on their own.”
Although Chemwerth has traditionally served U.S. customers, interest in Chinese-made APIs is rising elsewhere, according to Werth. Several Indian manufacturers of generic drugs, he explained, rely on Chemwerth’s quality assurance infrastructure in China to source Chinese APIs.
Advertisement
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter